Cited by 298Gut microbiota and healthLiver Disease Diagnosis and TreatmentOral microbiology and periodontitis research

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease

Open access

Schwimmer, Jeffrey B., Johnson, Jethro S., Angeles, Jorge E., Behling, Cynthia, Belt, Patricia H., Borecki, Ingrid, Bross, Craig, Durelle, Janis, Goyal, Nidhi P., Hamilton, Gavin, Holtz, Mary L., Lavine, Joel E., Mitreva, Makedonka, Newton, Kimberly P., Pan, Amy, Simpson, Pippa M., Sirlin, Claude B., Sodergren, Erica, Tyagi, Rahul, Yates, Katherine P., Weinstock, George M., Salzman, Nita H.·2019·Gastroenterology

DOI 10.1053/j.gastro.2019.06.028PMC PMC6756995

Open this paper in CoChat — free account

Abstract

Background & aims The intestinal microbiome might affect the development and severity of nonalcoholic fatty liver disease (NAFLD). We analyzed microbiomes of children with and without NAFLD.Methods We performed a prospective, observational, cross-sectional study of 87 children (age range, 8-17 years) with biopsy-proven NAFLD and 37 children with obesity without NAFLD (controls). Fecal samples were collected and microbiome composition and functions were assessed using 16S ribosomal RNA amplicon sequencing and metagenomic shotgun sequencing. Microbial taxa were identified using zero-inflated negative binomial modeling. Genes contributing to bacterial pathways were identified using gene set enrichment analysis.Results Fecal microbiomes of children with NAFLD had lower α-diversity than those of control children (3.32 vs 3.52, P = .016). Fecal microbiomes from children with nonalcoholic steatohepatitis (NASH) had the lowest α-diversity (control, 3.52; NAFLD, 3.36; borderline NASH, 3.37; NASH, 2.97; P = .001). High abundance of Prevotella copri was associated with more severe fibrosis (P = .036). Genes for lipopolysaccharide biosynthesis were enriched in microbiomes from children with NASH (P < .001). Classification and regression tree model with level of alanine aminotransferase and relative abundance of the lipopolysaccharide pathway gene encoding 3-deoxy-d-manno-octulosonate 8-phosphate-phosphatase identified patients with NASH with an area under the receiver operating characteristic curve value of 0.92. Genes involved in flagellar assembly were enriched in the fecal microbiomes of patients with moderate to severe fibrosis (P < .001). Classification and regression tree models based on level of alanine aminotransferase and abundance of genes encoding flagellar biosynthesis protein had good accuracy for identifying case children with moderate to severe fibrosis (area under the receiver operating characteristic curve, 0.87).Conclusions In an analysis of fecal microbiomes of children with NAFLD, we associated NAFLD and NASH with intestinal dysbiosis. NAFLD and its severity were associated with greater abundance of genes encoding inflammatory bacterial products. Alterations to the intestinal microbiome might contribute to the pathogenesis of NAFLD and be used as markers of disease or severity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2019.06.028

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data
McMurdie, P. J., & Holmes, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061217 · Cited by 21,942
UPARSE: highly accurate OTU sequences from microbial amplicon reads
Edgar, R. C. (2013) · Nature Methods · doi:10.1038/nmeth.2604 · Cited by 16,770
Non‐parametric multivariate analyses of changes in community structure
Clarke, K. R. (1993) · Australian Journal of Ecology · doi:10.1111/j.1442-9993.1993.tb00438.x · Cited by 14,449
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citation
Diet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100
SPECIES ASSEMBLAGES AND INDICATOR SPECIES:THE NEED FOR A FLEXIBLE ASYMMETRICAL APPROACH
Dufrêne, M., & Legendre, P. (1997) · Ecological Monographs · doi:10.1890/0012-9615(1997)067[0345:saaist]2.0.co;2 · Cited by 8,537
Human gut microbiome viewed across age and geography
Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., Magris, M., Hidalgo, G., Baldassano, R. N., Anokhin, A. P., et al. (2012) · Nature · doi:10.1038/nature11053 · Cited by 7,815
The human microbiome project
Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser-Liggett, C. M., Knight, R., & Gordon, J. I. (2007) · Nature · doi:10.1038/nature06244 · Cited by 6,091

Flagged first, then by citations

Show all 58 references

Sorted by citations

Items 101–200 of 298

Bioactive metabolites: A clue to the link between MASLD and CKD?
Chen, W., Zhang, J.-H., Chen, L., Byrne, C. D., Targher, G., Luo, L., Ni, Y., Zheng, M., & Sun, D. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0782 · Cited by 27
Meta-analysis of shotgun sequencing of gut microbiota in obese children with MASLD or MASH
Zöggeler, T., Kavallar, A. M., Pollio, A. R., Aldrian, D., Decristoforo, C., Scholl‐Bürgi, S., Müller, T., & Vogel, G. F. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2508951 · Cited by 31
Traditional Chinese medicine, liver fibrosis, intestinal flora: is there any connection?—a narrative review
Liu, Y.-T., Qi, S.-L., & Sun, K. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-2129 · Cited by 26
“, 2019, (58) High fat diet Firmicutes↑, Proteobacteria↑ Cross-sectional”
Result
The role of faecal microbiota transplantation in chronic noncommunicable disorders
Mullish, B. H., Tohumcu, E., Porcari, S., Fiorani, M., Tommaso, N. D., Gasbarrini, A., Cammarota, G., Ponziani, F. R., & Ianiro, G. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103034 · Cited by 25
Nutritional Approaches in Children with Overweight or Obesity and Hepatic Steatosis
Spiezia, C., Rosa, C. D., Fintini, D., Ferrara, P., Gara, L. D., & Khazrai, Y. M. (2023) · Nutrients · doi:10.3390/nu15112435 · Cited by 24
Farnesoid X receptor: From Structure to Function and Its Pharmacology in Liver Fibrosis
Ding, C., Wang, Z., Dou, X., Yang, Q., Ning, Y., Kao, S., Sang, X., Hao, M., Wang, K., Peng, M., et al. (2023) · Aging and Disease · doi:10.14336/ad.2023.0830 · Cited by 29
“This phenomenon might contribute to increased intestinal permeability and the promotion of a proinflammatory state, which is positively associated with liver fibrosis [188-190].”
Background
Ganoderma lucidum ethanol extracts ameliorate hepatic fibrosis and promote the communication between metabolites and gut microbiota g_Ruminococcus through the NF-κB and TGF-β1/Smads pathways
Zhang, J., Wang, W., Cui, X., Zhu, P.-L., Li, S., Yuan, S., Peng, D., & Peng, C. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117656 · Cited by 26
Prevotella copri—a potential next‐generation probiotic
Zang, X., Xiao, M., Yu, L., Chen, Y., Duan, H., Zhang, C., Zhao, J., Narbad, A., Chen, W., Tian, F., et al. (2024) · Food Frontiers · doi:10.1002/fft2.417 · Cited by 28
Liver tissue microbiota in nonalcoholic liver disease: a change in the paradigm of host-bacterial interactions
Sookoian, S. C., & Pirola, C. J. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-20-270 · Cited by 24
Characterization of Gut Microbiome in Liver Transplant Recipients With Nonalcoholic Steatohepatitis
Satapathy, S. K., Banerjee, P., Pierre, J. F., Higgins, D., Dutta, S., Heda, R. P., Khan, S. D., Mupparaju, V. K., Mas, V. R., Nair, S. P., et al. (2020) · Transplantation Direct · doi:10.1097/txd.0000000000001033 · Cited by 25
Changes in the intestinal microbiota of individuals with non-alcoholic fatty liver disease based on sequencing: An updated systematic review and meta-analysis
Cai, W., Qiu, T. H., Hu, W., & Fang, T. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299946 · Cited by 25
Multi-omics analyses of the gut microbiota and metabolites in children with metabolic dysfunction-associated steatotic liver disease
Du, L., Zhang, K., Liang, L., Yang, Y., Lu, D., Zhou, Y., Ren, T., Fan, J., Zhang, H., Wang, Y., et al. (2025) · mSystems · doi:10.1128/msystems.01148-24 · Cited by 25
“Consistently, Schwimmer et al. (6) compared the gut microbiota between children with obesity (controls) and those with NAFLD at different stages.”
Gut Microbiota Interactions With Obesity
Falalyeyeva, T. M., Chornenka, N., Cherkasova, L., Tsyryuk, O., Molchek, N., Kovalchuk, O. I., Kyriachenko, Y., Остапченко, Л. І., & Kobyliak, N. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00030-9 · Cited by 24
Proton pump inhibitors use and the risk of fatty liver disease: A nationwide cohort study
Pyo, J. H., Kim, T. J., Lee, H., Choi, S. C., Cho, S., Choi, Y., Min, Y. W., Min, B., Lee, J. H., Kang, M., et al. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15236 · Cited by 24
Microbiota-derived H2S induces c-kit+ cDC1 autophagic cell death and liver inflammation in metabolic dysfunction-associated steatohepatitis
Song, Y., Li, N., Jiang, S., Wang, K., Lv, G., Fan, Z., Du, X., Gao, W., Lei, L., Wang, Z., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57574-3 · Cited by 25
Non-alcoholic Fatty Liver and Liver Fibrosis Predictive Analytics: Risk Prediction and Machine Learning Techniques for Improved Preventive Medicine
Goldman, O., Ben‐Assuli, O., Rogowski, O., Zeltser, D., Shapira, I., Berliner, S. A., Zelber‐Sagi, S., & Shenhar‐Tsarfaty, S. (2021) · Journal of Medical Systems · doi:10.1007/s10916-020-01693-5 · Cited by 23
Polysaccharides from Ostrea rivularis rebuild the balance of gut microbiota to ameliorate non-alcoholic fatty liver disease in ApoE−/− mice
Zhu, L., Xiao, M., Luo, J., Li, S., Liu, W., Wu, J., & Song, Z. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123853 · Cited by 23
Faecal Microbiota Transplantation, Paving the Way to Treat Non-Alcoholic Fatty Liver Disease
Barrio, M. D., Lavín-Alconero, L., Santos‐Laso, Á., Arias, M., Odriozola, A., Rodríguez-Duque, J. C., Rivas, C., Iruzubieta, P., & Crespo, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076123 · Cited by 26
“Likewise, children with NAFLD also exhibited alterations in faecal microbiota, revealing an increase in Bacteroidetes and Proteobacteriae and a reduction in Firmicutes accompanied by a lower α-diversity [20].”
Background
Association between gut microbiota and hepatocellular carcinoma from 2011 to 2022: Bibliometric analysis and global trends
Chen, Z., Ding, C., Gu, Y., He, Y., Chen, B. Y., Zheng, S., & Li, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1120515 · Cited by 22
“Recent studies have demonstrated the stability of the gut microbiota and its metabolites is important factor for the maintenance of normal liver functions (33, 34).”
Background
Enterotypes of the Gut Microbial Community and Their Response to Plant Secondary Compounds in Plateau Pikas
Fan, C., Zhang, L., Fu, H., Liu, C., Li, W., Cheng, Q., Zhang, H., Jia, S., & Zhang, Y. (2020) · Microorganisms · doi:10.3390/microorganisms8091311 · Cited by 22
“reported that the Firmicutes-dominant enterotype, which is estimated to have the lowest overall bacterial growth rate [69], also exhibited a delayed return to equilibrium [14].”
Background
Links between gut microbiome, metabolome, clinical variables and non‐alcoholic fatty liver disease severity in bariatric patients
Schwenger, K. J. P., Sharma, D., Ghorbani, Y., Xu, W., Lou, W. Y. W., Comelli, E. M., Fischer, S. E., Jackson, T. D., Okrainec, A., & Allard, J. P. (2024) · Liver International · doi:10.1111/liv.15864 · Cited by 22
“4 In addition, specific taxa or metabolites can contribute to NAFLD development and disease severity 5 including advanced fibrosis.”
Background
Homeostasis of gut microbiota protects against polychlorinated biphenyl 126-induced metabolic dysfunction in liver of mice
Su, H., Liu, J., Wu, G., Long, Z., Fan, J., Xu, Z., Liu, J., Yu, Z., Cao, M., Liao, N., et al. (2020) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2020.137597 · Cited by 23
New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease
Hartmann, P., & Schnabl, B. (2021) · Seminars in Liver Disease · doi:10.1055/s-0040-1719174 · Cited by 22
“Pediatric patients with NASH have higher concentrations of Lactobacillus and lower proportions of Akkermansia when compared with NAFLD patients without NASH [48].”
Background
Distinct Gut Microbial Signature and Host Genetic Variants in Association with Liver Fibrosis Severity in Patients with MASLD
Satthawiwat, N., Jinato, T., Sutheeworapong, S., Tanpowpong, N., Chuaypen, N., & Tangkijvanich, P. (2024) · Nutrients · doi:10.3390/nu16121800 · Cited by 20
Lactiplantibacillus plantarum attenuate gossypol-induced hepatic lipotoxicity by altering intestinal microbiota for enriching microbial tryptophan metabolites in Nile tilapia (Oreochromis niloticus)
Ding, F.-F., Zhou, N.-N., Mao, Y.-J., Yang, J., Limbu, S. M., Galindo‐Villegas, J., Du, Z., & Zhang, M. (2025) · Microbiome · doi:10.1186/s40168-025-02172-0 · Cited by 20
“Evidently, patients with nonalcoholic fatty liver disease (NAFLD) exhibit reduced bacterial diversity in their gut microbiota, as well as an increased proportion of patho-bionts and a reduced abundance of beneficial bacteria [5, 6].”
New Perspectives in Pediatric Nonalcoholic Fatty Liver Disease: Epidemiology, Genetics, Diagnosis, and Natural History
Ko, J. S. (2019) · Pediatric Gastroenterology Hepatology & Nutrition · doi:10.5223/pghn.2019.22.6.501 · Cited by 21
“Bacterial genes for lipopolysaccharide biosynthesis were enriched in children with NASH, and genes for flagellar assembly were enriched in moderate to severe fibrosis [32].”
Background
Dual Role of Pregnane X Receptor in Nonalcoholic Fatty Liver Disease
Xu, Y., An, Z., Wang, S., Ni, Y., Zhou, M., Feng, Q., Gou, X., Xu, M., & Qi, Y. (2023) · Current Molecular Pharmacology · doi:10.2174/0118761429259143230927110556 · Cited by 19
Domestication Shapes the Community Structure and Functional Metagenomic Content of the Yak Fecal Microbiota
Fu, H., Zhang, L., Fan, C., Liu, C., Li, W., Li, J., Zhao, X., Jia, S., & Zhang, Y. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.594075 · Cited by 20
Amelioration of Non-Alcoholic Steatohepatitis by Atractylodes macrocephala Polysaccharide, Chlorogenic Acid, and Geniposide Combination Is Associated With Reducing Endotoxin Gut Leakage
Leng, J., Tian, H., Fang, Y., Hu, Y., & Peng, J. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.827516 · Cited by 19
“Lower alpha diversity was observed in the gut microbiome of patients with NAFLD (Schwimmer et al., 2019; Pan et al., 2021).”
Background
Fecal Metagenomics and Metabolomics Identifying Microbial Signatures in Non-Alcoholic Fatty Liver Disease
Pekkala, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054855 · Cited by 22
“[74] metagenomics NAFL, NASH and healthy, overweight”
BackgroundInfluential
Gut insulin action protects from hepatocarcinogenesis in diabetic mice comorbid with nonalcoholic steatohepatitis
Soeda, K., Sasako, T., Enooku, K., Kubota, N., Kobayashi, N., Ikushima, Y., Awazawa, M., Bouchi, R., Toda, G., Yamada, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42334-y · Cited by 16
“In addition, the abundance of Bacteroides vulgatus was also known to increase in the gut ﬂ ora of fatty liver patients 33, 34 .”
Gut microbiota and non-alcoholic fatty liver disease
Abenavoli, L., Procopio, A. C., Scarpellini, E., POLIMENI, N., AQUILA, I., LARUSSA, T., BOCCUTO, L., & Luzza, F. (2021) · Minerva Gastroenterology · doi:10.23736/s2724-5985.21.02896-5 · Cited by 19
Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives
Vimalesvaran, S., Vajro, P., & Dhawan, A. K. (2024) · Hepatology International · doi:10.1007/s12072-024-10691-5 · Cited by 18
“In paediatrics, a number of studies have thus far studied the relationship between the intestinal microbiome in children with MAFLD [34–38] (Table 1).”
Background
Pathogenesis of metabolic dysfunction-associated steatotic liver disease and donor liver damage
Gou, C., Zhang, W., Xu, H., Zhang, H., Ding, R., & Zhang, X. (2025) · iLiver · doi:10.1016/j.iliver.2025.100195 · Cited by 22
Altered gut microbiome associated with metabolic-associated fatty liver disease in Chinese children
Ji, J., Sun, J., Li, J., Xie, J., Xi, B., & Zhao, M. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.11.001 · Cited by 18
The role of the gut microbiome in graft fibrosis after pediatric liver transplantation
Qin, T., Fu, J., & Verkade, H. J. (2020) · Human Genetics · doi:10.1007/s00439-020-02221-8 · Cited by 18
Antibiotics attenuate diet-induced nonalcoholic fatty liver disease without altering intestinal barrier dysfunction
Brandt, A., Csarmann, K., Hernández-Arriaga, A. M., Baumann, A., Staltner, R., Halilbasic, E., Trauner, M. A., Camarinha‐Silva, A., & Bergheim, I. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109495 · Cited by 17
Fatty acid metabolization and insulin regulation prevent liver injury from lipid accumulation in Himalayan marmots
Bao, Z., Guo, C., Chen, Y., Li, C., Lei, T., Zhou, S., Qi, D., & Xiang, Z. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112718 · Cited by 17
Review of paediatric obesity and non‐alcoholic fatty liver disease—A focus on emerging non‐pharmacologic treatment strategies
Piester, T. L., Jagtap, N., & Kalapala, R. (2023) · Pediatric Obesity · doi:10.1111/ijpo.13067 · Cited by 16
“Approximately 20%–50% of the general paediatric population with NAFLD will have NASH at diagnosis.(10,27,28) Advanced fibrosis at diagnosis has been demonstrated in 10%–20% of these NAFLD cases.”
Background
Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets
Gruzdev, S., Podoprigora, I. V., & Gizinger, O. A. (2024) · Archives of Microbiology · doi:10.1007/s00203-023-03752-0 · Cited by 17
“Gut microbiota was different both from healthy controls and between various NAFLD stages (steatosis vs. steatohepatitis fibrosis/cirrhosis vs. HCC) (Boursier et al. 2016; Caussy et al. 2019; Kolodziejczyk et al. 2019; Schwimmer et al. 2019).”
A Literature Review of Glutathione Therapy in Ameliorating Hepatic Dysfunction in Non-Alcoholic Fatty Liver Disease
Nguyen, M. T., Lian, A., Guilford, F. T., & Venketaraman, V. (2025) · Biomedicines · doi:10.3390/biomedicines13030644 · Cited by 23
“Additionally, risk factors such as obesity, T2DM, chronic inflammation, and gut microbiota dysbiosis exacerbate oxidative stress, further promoting disease progression (Figure 1) [3,17,63].”
NAD metabolic therapy in metabolic dysfunction-associated steatotic liver disease: Possible roles of gut microbiota
Lu, X., Yang, R., Chen, Y., & Chen, D. (2024) · iScience · doi:10.1016/j.isci.2024.109174 · Cited by 16
Impact of Gut Microbiome on Gut Permeability in Liver and Gut Diseases
Saha, P., & Hartmann, P. (2025) · Microorganisms · doi:10.3390/microorganisms13061188 · Cited by 16
“MASLD is associated with intestinal dysbiosis, including reduced diversity and richness of the gut microbiome in adults and children [27–29].”
Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics
Pandey, H., Goel, P., Srinivasan, V. M., Tang, D. W. T., Wong, S. H., & Lal, D. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i6.106849 · Cited by 20
Relationship between thick or greasy tongue-coating microbiota and tongue diagnosis in patients with primary liver cancer
Zhang, Y., Zhao, H., Guo, Y., Meng, Y., Yu, S., Pan, B., & Zhai, X. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.903616 · Cited by 15
“, 2019), liver disease (Jia et al., 2019; Schwimmer et al., 2019), and other chronic diseases (Nishida et al.”
Background
Ecological shifts of salivary microbiota associated with metabolic-associated fatty liver disease
Wang, M., Yan, L.-Y., Qiao, C.-Y., Zheng, C.-C., Niu, C., Huang, Z., & Pan, Y. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1131255 · Cited by 16
The Role of Choline, Soy Isoflavones, and Probiotics as Adjuvant Treatments in the Prevention and Management of NAFLD in Postmenopausal Women
DiStefano, J. K. (2023) · Nutrients · doi:10.3390/nu15122670 · Cited by 15
The gut barrier and chronic diseases
Santilli, A., Stefanopoulos, S., & Cresci, G. A. M. (2022) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000820 · Cited by 15
Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics
Riccio, S., Melone, R., Vitulano, C., Guida, P., Maddaluno, I., Guarino, S., Marzuillo, P., del Giudice, E. M., & Sessa, A. D. (2022) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v11.i3.221 · Cited by 15
Metabolic dysfunction-associated fatty liver disease: advances in genetic and epigenetic implications
Pirola, C. J., & Sookoian, S. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000814 · Cited by 14
Integrative metabolomics highlights gut microbiota metabolites as novel NAFLD-related candidate biomarkers in children
Luo, J., Luo, M., Kaminga, A. C., Wei, J., Dai, W., Peng, Y., Zhao, K., Duan, Y., Xiao, X., Ouyang, S., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.05230-22 · Cited by 14
Implications of Microbiota and Immune System in Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease
Popov, J., Despot, T., Rodriguez, D. A., Khan, I. I., Mech, E., Khan, M. A., Bojadzija, M., & Pai, N. (2024) · Nutrients · doi:10.3390/nu16111668 · Cited by 15
A gut microbiota-independent mechanism shapes the bile acid pool in mice with MASH
Gillard, J., Roumain, M., Picalausa, C., Thibaut, M. M., Clerbaux, L., Tailleux, A., Staels, B., Muccioli, G. G., Bindels, L. B., & Leclercq, I. A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101148 · Cited by 16
Intestinal Microecology: An Important Target for Chinese Medicine Treatment of Non-alcoholic Fatty Liver Disease
Li, H., & Hu, Y. (2020) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-020-3268-3 · Cited by 14
Characteristics and variation of fecal bacterial communities and functions in isolated systolic and diastolic hypertensive patients
Wang, P., Dong, Y., Zuo, K., Han, C., Jiao, J., Yang, X., & Li, J. (2021) · BMC Microbiology · doi:10.1186/s12866-021-02195-1 · Cited by 14
“richness and diversity have been identified in several chronic diseases, such as HTN [13], Behcet’s disease [33], multiple sclerosis [34], and nonalcoholic fatty liver disease [35] by metagenomic shotgun sequencing, while in the current study, patients with IDH exhibit much deficient genes and a trend toward lower Sha…”
Background
Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities
Zhou, H., Huang, Y., Chen, C., Song, M., & Hylemon, P. B. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100120 · Cited by 17
The Origins of NAFLD: The Potential Implication of Intrauterine Life and Early Postnatal Period
Valentini, F., Rocchi, G., Gentilucci, U. V., Guarino, M. P. L., Altomare, A., & Carotti, S. (2022) · Cells · doi:10.3390/cells11030562 · Cited by 13
“copri [↑] Genes of LPS biosynthesis and flagellar assembly were significantly enriched in microbiomes from children NASH [103]”
Background
Epigenetics, 1-Carbon Metabolism, and Homocysteine During Dysbiosis
Singh, M., Hardin, S. J., George, A. K., Eyob, W., Stanišić, D., Pushpakumar, S. B., & Tyagi, S. C. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.617953 · Cited by 13
Clinical features and metabolic complications for non-alcoholic fatty liver disease (NAFLD) in youth with obesity
Barbieri, E., Santoro, N., & Umano, G. R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1062341 · Cited by 14
Cross‐linkage between bacterial taxonomy and gene functions: a study of metagenome‐assembled genomes of gut microbiota in adult non‐alcoholic fatty liver disease
Canivet, C. M., David, N., Pailhories, H., Briand, M., Guy, C. D., Bouchez, O., Hunault, G., Fizanne, L., Lannes, A., Oberti, F., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16262 · Cited by 13
Non-Alcoholic Fatty Liver Disease in Children
Kohli, R., Bove, K. E., & Xanthakos, S. A. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108918978.036 · Cited by 15
Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making
Pirola, C. J., & Sookoian, S. C. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2191190 · Cited by 12
Equol, a metabolite of gut microbiota, attenuates liver steatosis via the SIRT1/HNF4α pathway in NAFLD mice
Luo, Z., Yang, L., He, J., Han, Y., Rong, X., Luo, D., & Guo, J. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105640 · Cited by 12
Resolution of inflammation in chronic disease via restoration of the heat shock response (HSR)
Schroeder, H. T., Muller, C. H. D. L., Heck, T. G., Krause, M. D. S., & de Bittencourt, P. I. H. (2024) · Cell Stress and Chaperones · doi:10.1016/j.cstres.2024.01.005 · Cited by 12
“77 A reduction in gut microbiota species diversity has been observed in obesity and T2DM, 78,79 along with an imbalance between beneficial and harmful species.”
Background
Pediatric metabolic dysfunction–associated steatotic liver disease and the gut microbiome: from research landscape to targeted modulation
Jiang, L., Du, L.-D., Zeng, J., Chu, H., Peng, Z., & Fan, J. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0718 · Cited by 12
Lactucin alleviates liver fibrosis by regulating the TLR4-MyD88-MAPK/NF-κB signaling pathway through intestinal flora
Zhu, L., Lv, B., Gao, Y., & Qin, D. (2025) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2025.110341 · Cited by 11
Protein hydrolysate from Atlantic salmon (Salmo salar) improves aging-associated neuroinflammation and cognitive decline in rats by reshaping the gut microbiota and Th17/Treg balance
Guan, M.-Q., Yu, L., Gu, H., Fu, Q., Liu, M.-M., Li, K., Yang, X., Framroze, B., Guo, J., Wei, J., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141270 · Cited by 11
Prevotella copri-produced 5-aminopentanoic acid promotes pediatric metabolic dysfunction-associated steatotic liver disease
Xu, Q.-Y., Ren, T., Zhou, Y.-C., Xu, J., Du, L.-D., Hong, D.-Y., Zhang, Q., Chu, H., Peng, Z., Fan, J., et al. (2025) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2025.02.004 · Cited by 11
Beyond lipids: Novel mechanisms for parenteral nutrition–associated liver disease
Wichman, B. E., Nilson, J., Govindan, S., Chen, A., Jain, A., Arun, V., Derdoy, J., Krebs, J., & Jain, A. K. (2022) · Nutrition in Clinical Practice · doi:10.1002/ncp.10830 · Cited by 11
Characteristics of intestinal microbiota in C57BL/6 mice with non-alcoholic fatty liver induced by high-fat diet
Yan, G., Li, S., Wen, Y., Luo, Y., Huang, J., Chen, B., Lv, S., Chen, L., He, L., He, M., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1051200 · Cited by 11
“A study of children reported that the phyla Bacteroidetes and Proteobacteria were higher in NAFLD, whereas the phylum Firmicutes were higher in children who were simply overweight or obese (Schwimmer et al., 2019).”
Background
The Role of the Gastrointestinal Microbiome in Liver Disease
Shalaby, N., Samocha‐Bonet, D., Kaakoush, N. O., & Danta, M. (2023) · Pathogens · doi:10.3390/pathogens12091087 · Cited by 11
“This study and others conﬁrm the importance of dysbiosis in liver disease [72,75–77, 79, 80 ].”
Background
Recent Advancements in Known and Emerging Risk Factors of Hepatocellular Carcinoma
Hussain, M. M., Bi, F., Wang, J., Zhai, A., Li, F., & Hu, H. (2025) · Cancer Medicine · doi:10.1002/cam4.71330 · Cited by 11
Early-life exposure to gestational diabetes mellitus predisposes offspring to pediatric nonalcoholic fatty liver disease
Zhang, Q., Dong, Y., & Fan, J. (2023) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2023.12.007 · Cited by 11
Role of intestinal flora in the development of nonalcoholic fatty liver disease in children
Zhang, J., Shi, M., Zhao, C., Liang, G., Li, C., Ge, X., Pei, C., Kong, Y. Y., Li, D., Yang, W., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.01006-23 · Cited by 10
“Despite studies of the relationship between NAFLD and gut bacteria in animal models and humans (7, 10), limited research has been conducted on this issue in children, particularly concerning NAFL and NASH.”
Background
Gut microbes combined with metabolomics reveal the protective effects of Qijia Rougan decoction against CCl4-induced hepatic fibrosis
Li, X., Xu, X., Tao, S., Su, Y., Wen, L., Wang, D., Liu, J., & Feng, Q. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1347120 · Cited by 10
Targeting the gut-liver axis with dietary polyphenols to ameliorate metabolic dysfunction-associated steatotic liver disease: advances in molecular mechanisms
Hu, Z., He, Z., Wang, Y., Chu, Z., Zhou, Y., Li, W., Lu, J., Lin, Q., & Luo, F. (2025) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2025.2556470 · Cited by 12
“In pediatric patients with MASLD (8–17 years old), the α diversity of the gut microbiota is significantly reduced (Schwimmer et al. 2019).”
Pediatric nonalcoholic fatty liver disease and the microbiome: Mechanisms contributing to pathogenesis and progression
Salzman, N. H., & Schwimmer, J. B. (2021) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2021.05.003 · Cited by 11
Self-citation
Akkermansia muciniphila - A Potential Next-generation Probiotic for Non-alcoholic Fatty Liver Disease
Banerjee, G., Papri, S. R., Satapathy, S. K., & Banerjee, P. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201025666230915103052 · Cited by 10
Next generation of strain specific probiotics in diabetes treatment: the case of Prevotella copri
Abenavoli, L., Falalyeyeva, T. M., Pellicano, R., Fagoonee, S., & Kobyliak, N. M. (2021) · Minerva Endocrinology · doi:10.23736/s0391-1977.20.03376-3 · Cited by 10
The Association Between Prevotella copri and Advanced Fibrosis in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease
Zhang, D., Zhang, D., Pawar, S., Shera, S., Hernandez, L., Jacobs, J. P., & Dong, T. S. (2025) · Nutrients · doi:10.3390/nu17132145 · Cited by 11
“Other published work has shown that Prevotella was enriched in patients with cirrhosis as compared to healthy controls [29], and P. copri was the main driver of advanced fibrosis in MASLD pediatric patients [30].”
Understanding crosstalk between the gut and liver microbiome: pathogenesis to therapeutic approaches in liver cancer
Goyal, H., Fatima, K., & Kaur, J. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03840-9 · Cited by 11
Obesity, Metabolic Syndrome and MASLD in Children: Inflammation as the Missing Link—A Short Narrative Review
Podeanu, M.-A., Ionele, C. M., Sandu, R. E., Rogoveanu, I., Stepan, M. D., Niculescu, C., Cazacu, S. M., & Vintilescu, Ş. B. (2026) · Life · doi:10.3390/life16020310 · Cited by 11
“MASLD ranges from simple steatosis to steatohepatitis, fibrosis, and potentially—but most rarely—cirrhosis [12,13].”
Alterations in the Gut Microbiota and Hepatitis-B-Virus Infection in Southern Chinese Patients With Coexisting Non-Alcoholic Fatty Liver Disease and Type-2 Diabetes Mellitus
Han, W., Huang, C., Ji, Y., Zhou, L., Chen, J., & Hou, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.805029 · Cited by 9
Restoring polyamine levels by supplementation of spermidine modulates hepatic immune landscape in murine model of NASH
Szydlowska, M., Lasky, G., Oldham, S. N., Rivera, C., Ford, M., Sellman, B. R., Rhodes, C. J., & Cohen, T. S. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166697 · Cited by 9
Correlation of non-alcoholic fatty liver disease and gut microflora: clinical reports and treatment options
Jadhav, P. A., Thomas, A. B., Nanda, R. K., & Chitlange, S. S. (2024) · Egyptian Liver Journal · doi:10.1186/s43066-024-00327-6 · Cited by 9
“The association of changes in gut microbiota function with NAFLD were well studied by Schwimmer et al. [20].”
Background
An Update on the Role of the Microbiome in Non-alcoholic Fatty Liver Disease Pathogenesis, Diagnosis, and Treatment
Mouzaki, M., & Loomba, R. S. (2020) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-020-00290-2 · Cited by 8
The diagnostic conundrum in non-alcoholic fatty liver disease
Rosato, V., Masarone, M., Aglitti, A., & Persico, M. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00018 · Cited by 9
“87 and was based on the measurement of ALT together with the quantification of genes encoding flagellar biosynthesis proteins [161].”
Method
The role of nutrition in non-alcoholic fatty liver disease treatment in obese children.
Guimber, D., Debray, D., Bocquet, A., Briend, A., Chouraqui, J.-P., Darmaun, D., Feillet, F., Frelut, M., Hankard, R., Lapillonne, A., et al. (2022) · PubMed · doi:10.1016/j.arcped.2021.09.009 · Cited by 9
Benefits of Physical Exercise as Approach to Prevention and Reversion of Non-Alcoholic Fatty Liver Disease in Children and Adolescents with Obesity
Calcaterra, V., Magenes, V. C., Vandoni, M., Berardo, C., Marin, L., Bianchi, A., Cordaro, E., Silvestro, G., Silvestri, D., Pellino, V. C., et al. (2022) · Children · doi:10.3390/children9081174 · Cited by 9
Clearing Steatosis Prior to Liver Surgery for Colorectal Metastasis: A Narrative Review and Case Illustration
Peloso, A., Tihy, M., Moeckli, B., Rubbia‐Brandt, L., & Toso, C. (2022) · Nutrients · doi:10.3390/nu14245340 · Cited by 8
The influence of liver transplantation on the interplay between gut microbiome and bile acid homeostasis in children with biliary atresia
Waldner, B. J., Aldrian, D., Zöggeler, T., Oberacher, H., Oberhuber, R., Schneeberger, S., Messner, F., Schneider, A.-M., Kohlmaier, B., Lanzersdorfer, R., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000151 · Cited by 8
Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism
Kwan, S., Gonzales, K. A., Jamal, M. A., Stevenson, H. L., Tan, L., Lorenzi, P. L., Futreal, P. A., Hawk, E. T., McCormick, J. B., Fisher‐Hoch, S. P., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2399260 · Cited by 9
Hepatoprotective properties of water kefir: A traditional fermented drink and its potential role
Adnyana, I., Aligita, W., Singgih, M., & Sutrisno, E. (2023) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_29_22 · Cited by 11
“[7] Treatment for cirrhosis is based on the etiology and severity of liver damage.”
Background
Gut microbiota links to histological damage in chronic HBV infection patients and aggravates fibrosis via fecal microbiota transplantation in mice
Wang, F., Wu, Y., Ni, J., Xie, Q., Shen, J. F., Chen, H., Ma, C., Yao, Y., Wang, J., Xu, L., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.00764-25 · Cited by 7
“Some Bacteroides species, such as B. vulgatus , B. uniformis , and B. ovatus , have been linked to negative effects on energy and immune homeostasis in nonalcoholic fatty liver disease (20) and hepatic disorder.”
Proton pump inhibitor use is associated with increased liver steatosis
Yu, H., Li, M., Yang, B., Sun, H., Jiang, H., Liang, Z., Smayi, A., Wu, B., & Yang, Y. (2024) · Biomedical Reports · doi:10.3892/br.2024.1804 · Cited by 7
A Novel Antioxidant, Hydrogen-Rich Coral Calcium Alters Gut Microbiome and Bile Acid Synthesis to Improve Methionine-and-Choline-Deficient Diet-Induced Non-Alcoholic Fatty Liver Disease
Wu, H., Tsai, C.-S., Chao, T., Ou, H., & Tsai, L. (2024) · Antioxidants · doi:10.3390/antiox13060746 · Cited by 7
Gut phageome in Mexican Americans: a population at high risk for metabolic dysfunction-associated steatotic liver disease and diabetes
Kwan, S., Sabotta, C. M., Cruz, L. R., Wong, M. C., Ajami, N. J., McCormick, J. B., Fisher‐Hoch, S. P., & Beretta, L. (2024) · mSystems · doi:10.1128/msystems.00434-24 · Cited by 7
“Cross-sectional studies in humans identified specific bacterial taxonomic changes associated with MASLD development and progression (9–13).”
Background
Insights of gut-liver axis in hepatic diseases: Mechanisms, clinical implications, and therapeutic potentials
Jeyaraman, N., Jeyaraman, M., Mariappan, T., Muthu, S., Ramasubramanian, S., Sharma, S., Santos, G. S., da Fonseca, L. F., & Lana, J. F. (2024) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v15.i6.98146 · Cited by 7
Non-alcoholic fatty liver disease and the gut microbiota in adolescents: is there a relationship?
Amrousy, D. M. E., Ashry, H. E., Maher, S., Elsayed, Y., & Hasan, S. (2024) · BMC Pediatrics · doi:10.1186/s12887-024-05268-y · Cited by 8
Identification of commensal gut bacterial strains with lipogenic effects contributing to NAFLD in children
Wei, J., Luo, J., Yang, F., Dai, W., Pan, X., & Luo, M. (2024) · iScience · doi:10.1016/j.isci.2024.108861 · Cited by 9

Authors: Schwimmer, J. B., Johnson, J. S., Angeles, J. E., Behling, C., Belt, P. H., Borecki, I., Bross, C., Durelle, J., Goyal, N. P., Hamilton, G., Holtz, M. L., Lavine, J. E., Mitreva, M., Newton, K. P., Pan, A., Simpson, P. M., Sirlin, C. B., Sodergren, E., Tyagi, R., Yates, K. P., Weinstock, G. M., & Salzman, N. H.
Affiliations: University of California San Diego (US)
The Jackson Laboratory for Genomic Medicine (US)
Sharp Memorial Hospital (US)
Johns Hopkins University (US)
Washington University in St. Louis (US)
Medical College of Wisconsin (US)
Columbia University Irving Medical Center (US)
Corresponding author: Salzman, Nita H.
ORCID: Schwimmer, Jeffrey B.
Johnson, Jethro S.
Behling, Cynthia
Borecki, Ingrid
Goyal, Nidhi P.
Hamilton, Gavin
Holtz, Mary L.
Lavine, Joel E.
Mitreva, Makedonka
Newton, Kimberly P.
Pan, Amy
Simpson, Pippa M.
Sirlin, Claude B.
Sodergren, Erica
Tyagi, Rahul
Yates, Katherine P.
Weinstock, George M.
Salzman, Nita H.
Venue: Gastroenterology
Publisher: Elsevier BV
Published: 2019-10
Volume: 157
Issue: 4
Pages: 1109-1122
ISSN: 0016-5085 (ISSN-L)
DOI: 10.1053/j.gastro.2019.06.028
PMC: PMC6756995
OpenAlex: W2953761756
Cited by: 298
References: 58
Citations by year: 2026: 31 · 2025: 37 · 2024: 41 · 2023: 54 · 2022: 32 · 2021: 56 · 2020: 40 · 2019: 6
FWCI: 11.16
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Gastroenterology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
Funders: School of Medicine, University of California, San Diego
Office of Extramural Research, National Institutes of Health
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
Keywords: non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, liver fibrosis, gut microbiota, fecal microbiota, Prevotella copri, lipopolysaccharide biosynthesis, flagellar assembly, dysbiosis, alpha diversity, alanine aminotransferase, children, obesity, disease severity markers, 16S rRNA
MeSH terms: Gastrointestinal Microbiome, Adolescent, Bacteria, Child, Cross-Sectional Studies, DNA, Bacterial, Feces, Female, Humans, Intestines, Liver Cirrhosis, Male, Prospective Studies, RNA, Ribosomal, 16S, Severity of Illness Index, Case-Control Studies, Ribotyping, Host-Pathogen Interactions, Metagenome, Dysbiosis, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks